Health Care/Hospital
Akso Health Group Announces Launch of Exploratory Global Patient Support Initiative
QINGDAO, China, Feb. 3, 2026 /PRNewswire/ -- Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") today announced the launch of the an exploratory patient support program and a strategic cooperation with Nanning Duoling Research Institute. Adopting an integrated model of "Traditional ...
2026-02-03 22:00
6704
Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501
Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional milestone payment ofUSD 5 million from Menarini Group after first-in-patient dosing in a Phase 1 trial of MEN2501, highly differentiated small molecule KIF18A inhibitor in d...
2026-02-03 22:00
5625
BioDlink Modernizes Quality Management with Successful Go-Live of Veeva QMS
* BioDlink has successfully implemented Veeva QMS, marking a key milestone in its digital transformation and strengthening its GMP quality management capabilities. * It enables a standardized, data-driven quality framework, supporting compliance, efficiency, and long-term continuous improveme...
2026-02-03 21:00
2770
CEPI and Samsung Biologics collaborate to strengthen outbreak-ready vaccine production and global access
OSLO, Norway and INCHEON, South Korea, Feb. 3, 2026 /PRNewswire/ -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced a partnership to strengthen vaccine manufact...
2026-02-03 21:00
5110
Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPα Monoclonal Antibody for Advanced Solid Tumors
Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion's "In Global, For Global" collaboration strategy. NEWARK, Del. and NANJING, China, Feb. 3, 2026 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a globa...
2026-02-03 17:31
4351
ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- On January 11, as the global healthcare industry gathered inSan Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully convened ahead of J.P. Morgan 2026. ACROBiosystems, as a key strategic partner, joined hands with multiple enterpr...
2026-02-02 23:00
5492
SanegeneBio Announces RNAi Global Licensing Collaboration with Genentech
- SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech - SanegeneBio to receive $200 million upfront payment and will be eligible to receive development and commercialization milestone payments, totaling up to $1.5 billion, plus tiered royalties - Genentech wil...
2026-02-02 20:00
3413
Sanyou Bio's Decade: From an Intelligent Super-Trillion Antibody Library to the "Innovation Hub for Original Drug Discovery"
SHANGHAI, Jan. 31, 2026 /PRNewswire/ -- Amid the surging wave of innovation in China's biopharmaceutical industry, a decade is long enough to witness the full evolution of a sector—from its initial emergence and growth to fundamental transformation. In 2015, as regulatory reform ignited local in...
2026-01-31 16:15
7752
Global Appeal 2026 Highlights Education as the Key to Ending Leprosy Stigma and Discrimination
--Launch Ceremony in Brussels Preceded by Royal Audience-- TOKYO, Jan. 30, 2026 /PRNewswire/ -- The 2026 Global Appeal to End Stigma and Discrimination Against Persons Affected by Leprosy was launched inBrussels, Belgium on January 29 at an event co-hosted by Education International and the Sasa...
2026-01-30 21:11
5195
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, to...
2026-01-30 21:00
8313
NEXTBIOMEDICAL Secures Health Canada Approval for Nexsphere-F™ in Musculoskeletal Pain Embolization
SEOUL, South Korea, Jan. 29, 2026 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based inSouth Korea, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval fro...
2026-01-29 22:00
4667
MicuRx Announces FDA Clearance of IND Application to Proceed to Phase 2a Trial of MRX-5 in Patients with Mycobacterium abscessus Pulmonary Disease
FOSTER CITY, Calif., Jan. 29, 2026 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc. ("MicuRx"), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for drug-resistant bacterial infections, recently announced that the U.S. Food and Drug Administration (FDA) ...
2026-01-29 21:02
5143
XtalPi Convenes Global Experts to Shape the Future of Molecular Glue Drug Discovery: From Serendipity to Precision
* Global thought leaders presented cutting-edge research at the 2026 International Symposium on Molecular Glue Drug Discovery. * XtalPi unveils the AI-driven XGlue™ platform to enable rapid, closed-loop molecular glue drug discovery. * Cross-sector discussions emphasized the need for bridgin...
2026-01-29 21:00
4777
Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"
HONG KONG, Jan. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-depth analysis of 20 key drugs poised to define the trajectory of the ...
2026-01-29 12:51
3991
WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody
SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific ...
2026-01-29 10:39
6577
QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- QureBio Ltd., a clinical-stage biotech company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today revealed in 2026 ASCO abstract submission a...
2026-01-29 10:21
3861
Nona Biosciences Co-founds Innovative Alliance for Translational Medicine in Immunological Diseases, Advancing a New IIT-Driven Ecosystem
CAMBRIDGE, Mass., Jan. 28, 2026 /PRNewswire/ -- Recently, as a core co-founder and co-organizer, Nona Biosciences participated in the launch of the "Innovative Alliance for Translational Medicine in Immunological Diseases" (the "Alliance") and attended its inauguration ceremony. The Alliance brin...
2026-01-29 09:00
3209
Global Appeal 2026: Education as the Key to Ending Leprosy Stigma and Discrimination
— Launch Event in Brussels Will Be Live-Streamed Worldwide — TOKYO, Jan. 28, 2026 /PRNewswire/ -- The transformative power of education in replacing fear with knowledge and prejudice with empathy lies at the heart of the Global Appeal 2026 to End Stigma and Discrimination against Persons Affect...
2026-01-28 21:00
3121
Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating
* Ranked in the top one percent among more than 150,000 companies assessed globally * Recognized for strengthened sustainability management across all four assessment categories INCHEON, South Korea, Jan. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract developm...
2026-01-28 20:00
4588
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments SEOUL, South Korea, Jan. 27, 2026 /PRNewswire/ -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obes...
2026-01-28 12:08
3828
Week's Top Stories
Most Reposted
Agoda Launches Free Global eSIMs for VIP Diamond Members
[Picked up by 322 media titles]
2026-02-10 14:00
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 320 media titles]
2026-02-16 10:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Blackpanda Japan Announces Strategic Partnership with SoftBank to Strengthen Cyber Incident Response in Japan
[Picked up by 298 media titles]
2026-02-10 13:31Carro unveils quirky generative AI ad campaign highlighting its 'Surprisingly Short' AI-enabled car-selling process
[Picked up by 296 media titles]
2026-02-11 11:00
Most Read
Agoda Launches Free Global eSIMs for VIP Diamond Members
2026-02-10 14:00
6932
Datasea Reports Second Fiscal Quarter 2026 Results
2026-02-12 22:20
6827
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
6662
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
2026-02-12 21:56
5893
